ASCO Round-Up: Array, Kite, Exelixis, Pfizer/Merck KGAA, Mylan, Novartis
Executive Summary
The annual American Society of Clinical Oncology (ASCO) conference has been ongoing the last several days in Chicago, giving companies the chance to showcase their work in a range of cancers. Here's a look at some of the highlights.
You may also be interested in...
Biocon Stays The Course For Neulasta, Herceptin Biosimilars
Biocon reported robust first-quarter numbers and remains upbeat on the prospects of taking its biosimilars including pegfilgrastim and trastuzumab to Europe and the US notwithstanding regulatory setbacks faced by some seasoned competitors recently.
Biocon Stays The Course For Neulasta, Herceptin Biosimilars
Biocon reported robust first-quarter numbers and remains upbeat on the prospects of taking its biosimilars including pegfilgrastim and trastuzumab to Europe and the US notwithstanding regulatory setbacks faced by some seasoned competitors recently.
Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market
At the ASCO 2016 meeting, researchers compared results for kidney cancer trials; Bristol's Opdivo gets kudos for tolerability.